Compare Estee Lauder Companies Inc (EL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Mesoblast Limited — how do they compare? Estee Lauder Companies Inc trades at $88.01 (market cap $31.76B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Estee Lauder Companies Inc is far larger — about 14.4× Mesoblast Limited's market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| EL | MESO | |
|---|---|---|
Market Cap | $31.76B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $119.61 | $20.96 |
52-Week Low | $67.23 | $12.88 |
Enterprise Value | $37.93B | $2.21B |
Dividend Yield | 1.59% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
